NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

Core Points - NLS Pharmaceutics Ltd. plans to execute a reverse share split at a ratio of 1-for-10, effective on October 30, 2025, in conjunction with a merger with Kadimastem Ltd. [1][2] - Following the reverse split, the company's common shares will trade under the new symbol "NCEL" starting October 31, 2025 [1][2] - The reverse split will also apply to preferred shares and preferred participation certificates at the same 1-for-10 ratio [3] Company Structure Post-Merger - After the reverse split and merger, the company's registered capital will consist of CHF 282,908.80, divided into 5,533,183 common shares and 124,993 preferred shares, among other capital structures [4] - The total outstanding common shares will be 4,558,378, with additional shares issuable upon the exercise of pre-funded warrants [6] Shareholder Impact - No fractional shares will be issued; instead, cash will be provided for any fractional shares resulting from the reverse split [5] - The reverse split will not affect shareholders' percentage ownership or voting power, aside from minor adjustments due to fractional shares [5]